Incyte is trading at $120.00, down 7.6% in after-hours trading following its second-quarter 2026 earnings release and updated guidance.
- While revenue and EPS exceeded analyst expectations, the results were significantly bolstered by a one-time Opzelura benefit related to a CMS settlement.
- Investors are reassessing the sustainability of the company's growth outlook, leading to profit-taking and a reset of gains following a strong regular-session rally.